Assessment of Tie2-Rejuvenated Nucleus Pulposus Cell Transplants from Young and Old Patient Sources Demonstrates That Age Still Matters
Authors:
- Yuto OtaniYOYuto Otani
- Jordy ScholJordy Schol
- Daisuke SakaiDaisuke Sakai
- Yoshihiko NakamuraYNYoshihiko Nakamura
- Kosuke SakoKSKosuke Sako
- Takayuki WaritaTWTakayuki Warita
- Shota TamagawaSTShota Tamagawa
- Luca AmbrosioLuca Ambrosio
- Daiki MunesadaDMDaiki Munesada
- Shota OgasawaraSOShota Ogasawara
- Erika MatsushitaEMErika Matsushita
- Asami KawachiAKAsami Kawachi
Open Access
- 30 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8335
Abstract
Cell transplantation is being actively explored as a regenerative therapy for discogenic back pain. This study explored the regenerative potential of Tie2+ nucleus pulposus progenitor cells (NPPCs) from intervertebral disc (IVD) tissues derived from young (60 years of age) patient donors. We employed an optimized culture method to maintain Tie2 expression in NP cells from both donor categories. Our study revealed similar Tie2 positivity rates regardless of donor types following cell culture. Nevertheless, clear differences were also found, such as the emergence of significantly higher (3.6-fold) GD2 positivity and reduced (2.7-fold) proliferation potential for older donors compared to young sources. Our results suggest that, despite obtaining a high fraction of Tie2+ NP cells, cells from older donors were already committed to a more mature phenotype. These disparities translated into functional differences, influencing colony formation, extracellular matrix production, and in vivo regenerative potential. This study underscores the importance of considering age-related factors in NPPC-based therapies for disc degeneration. Further investigation into the genetic and epigenetic alterations of Tie2+ NP cells from older donors is crucial for refining regenerative strategies. These findings shed light on Tie2+ NPPCs as a promising cell source for IVD regeneration while emphasizing the need for comprehensive understanding and scalability considerations in culture methods for broader clinical applicability.Keywords
Funding Information
- TUNZ Pharma Corporation (JP23ym0126124)
- Japanese Agency for Medical research and Development (AMED) (JP23ym0126124)
This publication has 131 references indexed in Scilit:
- Extracellular Vesicles as an Emerging Treatment Option for Intervertebral Disc Degeneration: Therapeutic Potential, Translational Pathways, and Regulatory ConsiderationsAdvanced Healthcare Materials, 2021
- Pathomechanism of intervertebral disc degenerationJOR SPINE, 2020
- Prognostic factors in the progression of intervertebral disc degeneration: Which patient should be targeted with regenerative therapies?JOR SPINE, 2019
- Annulus fibrosus cell sheets limit disc degeneration in a rat annulus fibrosus injury modelJOR SPINE, 2019
- Controversies in regenerative medicine: Should intervertebral disc degeneration be treated with mesenchymal stem cells?JOR SPINE, 2019
- Osteoarthritis and intervertebral disc degeneration: Quite different, quite similarJOR SPINE, 2018
- Leaping the hurdles in developing regenerative treatments for the intervertebral disc from preclinical to clinicalJOR SPINE, 2018
- Critical aspects and challenges for intervertebral disc repair and regeneration—Harnessing advances in tissue engineeringJOR SPINE, 2018
- Successful fishing for nucleus pulposus progenitor cells of the intervertebral disc across speciesJOR SPINE, 2018
- Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine modelJOR SPINE, 2018